Femme Homme
- | Pays :
- Australia
- United States
- Argentina
- Les 2 autres...
- | Organes : -
- | Spécialités : -
Extrait
The purpose of this phase II, randomized, open-label clinical trial is to study 2 schedules of single-agent Irinotecan in women with metastatic breast cancer who have experienced failure of prior therapy with an anthracycline, a taxane, and capecitabine. Patients will receive Irinotecan capsules either once each day for 5 days, or once a day for 14 days in 3 week cycles.
Critère d'inclusion
- Breast Neoplasms